SwePub
Sök i LIBRIS databas

  Utökad sökning

onr:"swepub:oai:research.chalmers.se:2018c501-e6ee-499e-8e98-fdc9371297d5"
 

Sökning: onr:"swepub:oai:research.chalmers.se:2018c501-e6ee-499e-8e98-fdc9371297d5" > Denosumab reduces t...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00004291naa a2200685 4500
001oai:research.chalmers.se:2018c501-e6ee-499e-8e98-fdc9371297d5
003SwePub
008171010s2012 | |||||||||||000 ||eng|
0247 a https://research.chalmers.se/publication/1716052 URI
0247 a https://doi.org/10.1002/jbmr.16062 DOI
040 a (SwePub)cth
041 a engb eng
042 9 SwePub
072 7a art2 swepub-publicationtype
072 7a ref2 swepub-contenttype
1001 a McCloskey, Eugene V4 aut
2451 0a Denosumab reduces the risk of osteoporotic fractures in postmenopausal women, particularly in those with moderate to high fracture risk as assessed with FRAX.
264 c 2012-06-15
264 1b Wiley,c 2012
520 a Denosumab has been shown to reduce the incidence of vertebral, nonvertebral, and hip fractures. The aim of the current study was to determine whether the antifracture efficacy of denosumab was dependent on baseline fracture probability assessed by FRAX. The primary data of the phase 3 FREEDOM study of the effects of denosumab in women with postmenopausal osteoporosis were used to compute country-specific probabilities using the FRAX tool (version 3.2). The outcome variable comprised all clinical osteoporotic fractures (including clinical vertebral fractures). Interactions between fracture probability and efficacy were explored by Poisson regression. At baseline, the median 10-year probability of a major osteoporotic fracture (with bone mineral density) was approximately 15% and for hip fracture was approximately 5% in both groups. In the simplest model adjusted for age and fracture probability, treatment with denosumab over 3 years was associated with a 32% (95% confidence interval [CI] 20% to 42%) decrease in clinical osteoporotic fractures. Denosumab reduced fracture risk to a greater extent in those at moderate to high risk. For example, at 10% probability, denosumab decreased fracture risk by 11% (p = 0.629), whereas at 30% probability (90th percentile of study population) the reduction was 50% (p = 0.001). The reduction in fracture was independent of prior fracture, parental history of hip fracture, or secondary causes of osteoporosis. A low body mass index (BMI) was associated with greater efficacy. Denosumab significantly decreased the risk of clinical osteoporotic fractures in postmenopausal women. Overall, the efficacy of denosumab was greater in those at moderate to high risk of fracture as assessed by FRAX.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Endokrinologi och diabetes0 (SwePub)302052 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Endocrinology and Diabetes0 (SwePub)302052 hsv//eng
653 a Risk Assessment
653 a Probability
653 a prevention & control
653 a Female
653 a Risk
653 a 80 and over
653 a Proportional Hazards Models
653 a Middle Aged
653 a Bone Density Conservation Agents
653 a Monoclonal
653 a Fracture Healing
653 a Algorithms
653 a Aged
653 a therapeutic use
653 a Osteoporotic Fractures
653 a Humans
653 a Postmenopause
653 a Placebos
653 a drug therapy
653 a Body Mass Index
653 a Osteoporosis
653 a Antibodies
653 a Humanized
7001 a Johansson, Helena,d 19814 aut
7001 a Odén, Anders,d 19424 aut
7001 a Austin, Matt4 aut
7001 a Siris, Ethel4 aut
7001 a Wang, Andrea4 aut
7001 a Lewiecki, E Michael4 aut
7001 a Lorenc, Roman4 aut
7001 a Libanati, Cesar4 aut
7001 a Kanis, John A4 aut
7730 t Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Researchd : Wileyg 27:7, s. 1480-6q 27:7<1480-6x 1523-4681
7730 t Journal of Bone and Mineral Researchd : Wileyg 27:7, s. 1480-6q 27:7<1480-6x 0884-0431
8564 u http://dx.doi.org/10.1002/jbmr.1606y FULLTEXT
8564 u https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/jbmr.1606
8564 8u https://research.chalmers.se/publication/171605
8564 8u https://doi.org/10.1002/jbmr.1606

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy